Research & Development
Affinity discovers potent antibodies that can completely neutralize SARS-CoV-2 infection
2 July 2020 -

Antibody discovery company Affinity Biosciences Pty Ltd reported on Wednesday the discovery of potent antibody binding to the SARS-CoV-2 virus spike protein that blocks the activity to prevent the virus from gaining a solid position in healthy people exposed to its infection.

Based in Melbourne, the company discovered several candidate antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. The antibodies block the virus's spike protein from binding to the human receptor. Additionally, The Doherty Institute has also confirmed that these antibodies can completely neutralize SARS-CoV-2 infection in a single figure microgram / ml concentration in five-day virus neutralization assays. The antibodies have a high affinity for the SARS-CoV-2 spike protein of about 20 picomolar.

The company will seek an expedited process that enables the rapid manufacture of its antibodies to Good Manufacturing Practice (GMP) standards for clinical trials. Identification of expedited development routes with regulatory agencies (TGA, FDA and EMA) discussions are underway with governments, NGOs and pharmaceutical companies to achieve accelerated development and commercial distribution.